APLS

Apellis Pharmaceuticals, Inc.

67.49 USD
+0.60 (+0.90%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Apellis Pharmaceuticals, Inc. stock is up 1.46% since 30 days ago. The next earnings date is Feb 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 85.71% of the previous 6 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 6 PUTs, 4 CALLs. 80% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
07 Feb 14:57 15 Mar, 2024 70.00 PUT 49 60
07 Feb 14:58 15 Mar, 2024 70.00 PUT 50 60
07 Feb 20:53 20 Dec, 2024 80.00 CALL 60 1609
09 Feb 16:55 16 Jan, 2026 70.00 PUT 102 13
14 Feb 17:55 16 Jan, 2026 105.00 CALL 39 0
14 Feb 19:30 16 Jan, 2026 90.00 CALL 31 44
14 Feb 19:53 17 Jan, 2025 95.00 CALL 155 155
15 Feb 14:47 15 Mar, 2024 60.00 PUT 171 234
15 Feb 16:32 16 Jan, 2026 80.00 PUT 11 0
15 Feb 17:48 16 Jan, 2026 85.00 PUT 32 26

About Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases.

  • Mizuho
    Fri Feb 16, 18:42
    hold
    confirm
  • Baird
    Tue Feb 6, 13:32
    buy
    confirm
  • Jefferies
    Mon Feb 5, 05:18
    buy
    upgrade
  • Oppenheimer
    Tue Jan 30, 09:24
    buy
    confirm
  • Needham
    Wed Jan 24, 05:45
    buy
    confirm